ALFA FinderNSE filing, NSE: VENUSREM. Summary written from the filing by ALFA Finder's alert engine.
Venus Remedies Ltd: key numbers
- Share price
- ₹1,447.90
- Market cap
- ₹1,935 Cr
- Revenue (annual)
- ₹769.6 Cr
- Net profit (annual)
- ₹102.8 Cr
- P/E (TTM)
- 15.9×Sector 43.8×
- Promoter holding
- 41.76%+0.00% QoQ
- FII holding
- 3.14%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Venus Remedies Ltd
All →Venus Remedies Other Announcement
Venus Remedies relayed social media posts about a SEBI special window for re-lodging physical share transfer requests. The notice carries no monetary event.
Venus Remedies Q2 FY27 Results: Net Profit ₹25.6 Cr, Up 27.4% YoY
Venus Remedies Ltd reported revenue from operations of ₹218.8 Cr (+13.5% YoY) and net profit of ₹25.6 Cr (+27.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹25.6 Cr · +27.4% YoY
Venus Remedies Regulatory Approval
Venus Remedies Limited secured five marketing authorizations for drugs including Vancomycin and Meropenem across Kazakhstan, Peru, Kuwait, and Argentina. These regulatory approvals expand its global pharmaceutical portfolio.
Venus Remedies Board Meeting Date
Venus Remedies will hold a board meeting on 26th October 2026 to consider and approve its unaudited standalone and consolidated financial results for the September quarter.
Venus Remedies Other Announcement
Venus Remedies Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026, as required by SEBI regulations.
Venus Remedies Other Announcement
Venus Remedies Limited has announced a change in its Corporate Identification Number (CIN) following the alteration of its Memorandum of Association.
Other board meeting outcome announcements
All →Shri Keshav Cements & Infra Board Meeting Outcome
Shri Keshav Cements' board approved un-audited financial and segment-wise revenue results for the quarter and half-year ended 30 September 2026. No other material decisions were transacted.
Balmer Lawrie Investments Board Meeting Outcome
Balmer Lawrie Investments appointed M/s. K. K. Chanani & Associates as Statutory Auditor for FY 2026-27 under Section 139(5), per a C&AG letter. The appointment is effective from 10 November 2026.
- Execution
- FY 2026-27
Jiwanram Sheoduttrai Industries Board Meeting Outcome
Jiwanram Sheoduttrai's board approved convening its 29th AGM on 30 November 2026 and re-appointing a retiring non-executive director. The board also approved the FY2025-26 Board's Report.
Finolex Cables Board Meeting Outcome
Finolex Cables' board approved amending its insider trading code of conduct on 7 November 2026. Amended code was filed under PIT Regulation 8(2).
Chatterbox Technologies Board Meeting Outcome
Chatterbox's board approved a Rs. 7 crore related-party ceiling with its UAE subsidiary and a vendor change for IPO funds. Monitoring agency and deviation reports were also noted.
BCC Fuba India Board Meeting Outcome
BCC Fuba India's board met on November 6, 2026 and took note of consolidated related party transactions for the half year ended September 30, 2026. No financial results, capital raise or other material decision was reported.